Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|January 20, 2024
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancerSara M Tolaney, Valentina Guarneri, Jae Hong Seo, et al.Frontiers in Oncology|September 28, 2020
Immune-Related Gene Expression and Cytokine Secretion Is Reduced Among African American Colon Cancer PatientsJenny Paredes, Jovanny Zabaleta, Jone Garai, et al.NPJ Breast Cancer|April 27, 2026
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trialJoyce O'Shaughnessy, Francois-Clement Bidard, Patrick Neven, et al.European Stroke Journal|May 22, 2025
European Stroke Organisation (ESO) guideline on motor rehabilitationMargit Alt Murphy, Maria Munoz-Novoa, Charlotte Heremans, et al.Pain|September 9, 2024
Extended reality used in the treatment of phantom limb pain: a multicenter, double-blind, randomized controlled trialEva Lendaro, Corry K Van der Sluis, Liselotte Hermansson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy OutcomesPriya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.JAMA Oncology|June 2, 2022
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical TrialMiguel Martin, Roberto Hegg, Sung-Bae Kim, et al.The Lancet. Oncology|December 9, 2022
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialStephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, et al.JACC. Cardiovascular Interventions|May 26, 2026
Characteristics of Coronary Intra- or Extramedial Hematomas Causing Emergent Return to Catheterization Laboratory After Percutaneous Coronary InterventionTakunori Tsukui, Ge Jin, Kei Yamamoto, et al.Nature Genetics|May 1, 2012
A genome-wide association study identifies susceptibility loci for Wilms tumorClare Turnbull, Elizabeth R Perdeaux, David Pernet, et al.Pageof 6